iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology treatments for patients, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a business update.

"Our team's rigorous focus and execution over the past twelve months lays the foundation for a potentially decisive 2025 for iTeos. As we pursue several clinical trials to evaluate the combination of belrestotug + dostarlimab in collaboration with GSK, we look forward to the interim results of the GALAXIES Lung-201 study in the second quarter of 2025, as they will play a decisive role in shaping the next phase of development of our flagship program," said Michel Detheux, Ph.D., President and CEO of iTeos. "In parallel, we are continuing to accelerate the development of two Phase I therapeutic candidates that have the potential to become best- or first-in-class and fundamentally redefine the contours of the immuno-oncology industry. With $655 million in cash and room to maneuver through 2027, we are ready to take bold steps to advance our innovative science and bring new treatments to those who need them most.